Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FJUW2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,318
Award facts
- Contract value 100% obligated
- $19,318.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $19,318.30 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for NUCALA 100 mg/ml auto-injector units. The delivery order, issued on December 30, 2025, with a completion date of December 31, 2025, utilizes firm fixed-price pricing and was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The place of performance is Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. That underlying IDC, awarded on November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. The PPV-G GEN V program authorizes the issuance of firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense military healthcare facility operations globally. NUCALA is a specialty pharmaceutical biologic agent used in immunology treatment, reflecting the contractor's demonstrated capability to supply specialized pharmaceuticals to federal military medical systems.
Quick answers
Who was awarded contract SPE2DR26FJUW2?
SPE2DR26FJUW2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 30, 2025.
How much is contract SPE2DR26FJUW2 worth?
The government has obligated $19,318 on SPE2DR26FJUW2.
Is contract SPE2DR26FJUW2 an order under another contract?
Yes. SPE2DR26FJUW2 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUW2 competed?
The extent of competition for SPE2DR26FJUW2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award